Looking at blood samples from 299 heart patients, researchers at Ohio State University found that those who had suffered a heart attack were the most likely to have inflammatory proteins circulating in their blood compared to patients with less acute symptoms. And having more of one of these proteins in the blood was linked to the presence of antibodies that signal a latent Epstein-Barr virus (EBV) reactivation.
To date, these relationships have been hard to find because scientists have been unable to detect evidence of a virus in diseased areas of the cardiovascular system.
In this study, however, the researchers instead looked for antibodies against a protein that can be produced even when only partial or incomplete reactivation of Epstein-Barr EBV occurs. And when this antibody was detected, it was associated with immune system malfunctions connected to inflammation – a known risk factor for heart disease.
Identifying a solid link between a reactivated virus and heart disease is important because of the prevalence of EBV, a human herpes virus that causes infectious mononucleosis and several different types of tumors. An estimated 95 percent of Americans have been infected with the virus by adulthood, and once a person is infected, the virus remains dormant in the body. It can be reactivated without causing symptoms of illness, but reactivation has potential to create chaos in the immune system.
Stress is a known predictor of reactivation of EBV, meaning virus reactivation could be a mechanism by which stress leads to chronic inflammation and eventually cardiovascular diseases.
“In the big picture, this may help clarify the role these viruses play in heart disease,” said co-author Ron Glaser, director of Ohio State’s Institute for Behavioral Medicine Institute (IBMR) and professor of molecular virology, immunology and medical genetics. “And it makes sense, because we know that some viral proteins can induce inflammation, affecting the lining of blood vessels, so that inflammation is in the right place to function as a significant risk factor for heart disease.”
The research is published in the online journal PLOS ONE.
The patients whose blood was sampled for the study were undergoing angioplasty to clear narrow arteries. Researchers tested their blood for the presence of numerous cytokines – proteins that signal the presence of inflammation – as well as for antibody to an EBV encoded viral protein called dUTPase. This protein is produced early in the process of viral reactivation, and may be present even if signs of the virus itself cannot be detected.
Co-author Marshall Williams, professor of molecular virology, immunology and medical genetics, uses a highly sensitive method to detect these antibodies, and hopes to develop an equally effective technique that could be put to use in clinical laboratories.
Patients who had had acute myocardial infarction – a heart attack – were the most likely to have the highest measures of two cytokines, interleukin-6 (IL-6) and intercellular adhesion molecule 1 (ICAM-1) in their blood compared to patients whose main symptom was chest pain.
Researchers also identified a strong relationship between circulating concentrations of ICAM-1 and detectable antibodies to EBV dUTPase. In fact, the highest values of ICAM-1 were found in patients who had had a heart attack and were positive for the dUTPase protein. A similar trend was seen with IL-6, but the finding could have been attributed to chance.
“This study provides the essential clinical corroboration of this mechanism showing enhanced levels of proinflammatory proteins in the blood of patients with acute coronary events and detectable levels of the EBV-related protein,” said Philip Binkley, professor of cardiovascular medicine and epidemiology at Ohio State and a lead author of the study.
Additional co-authors on this work include Glen Cooke and Amanda Lesinski of the Division of Cardiovascular Medicine; Min Chen and Bryon Laskowski of the IBMR; James Waldman of the Department of Pathology; and Maria-Eugenia Ariza and Deborah Knight of the Department of Molecular Virology, Immunology and Medical Genetics. Co-author Mackenzie Taylor, Binkley and Cooke also are investigators in the Davis Heart and Lung Research Institute.
Contact: Philip Binkley, (614) 293-8963; Philip.Binkley@osumc.edu or Ron Glaser, (614) 293-0178; Ronald.Glaser@osumc.edu
Written by Emily Caldwell, (614) 292-8310; Caldwell.firstname.lastname@example.org
Further reports about: > Epstein-Barr > Medicine > Ohio > beruflicher Stress > blood sample > blood vessel > cardiovascular disease > heart disease > immune system > inflammatory proteins > medical genetics > molecular virology > proteins > reactivation > risk factor > vascular disease > viral protein
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences